These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
874 related articles for article (PubMed ID: 25681684)
1. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells. Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684 [TBL] [Abstract][Full Text] [Related]
2. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells. Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225 [TBL] [Abstract][Full Text] [Related]
3. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines. Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688 [TBL] [Abstract][Full Text] [Related]
4. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475 [TBL] [Abstract][Full Text] [Related]
5. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids. Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799 [TBL] [Abstract][Full Text] [Related]
6. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. Singh RK; Gaikwad SM; Jinager A; Chaudhury S; Maheshwari A; Ray P Cancer Lett; 2014 Nov; 354(2):254-62. PubMed ID: 25157649 [TBL] [Abstract][Full Text] [Related]
7. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Craveiro V; Yang-Hartwich Y; Holmberg JC; Joo WD; Sumi NJ; Pizzonia J; Griffin B; Gill SK; Silasi DA; Azodi M; Rutherford T; Alvero AB; Mor G Cancer Med; 2013 Dec; 2(6):751-62. PubMed ID: 24403249 [TBL] [Abstract][Full Text] [Related]
8. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137 [TBL] [Abstract][Full Text] [Related]
9. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer. Westhoff GL; Chen Y; Teng NNH Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634 [TBL] [Abstract][Full Text] [Related]
10. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells. Sun NK; Huang SL; Chang TC; Chao CC J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725 [TBL] [Abstract][Full Text] [Related]
12. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins. Li Z; Block MS; Vierkant RA; Fogarty ZC; Winham SJ; Visscher DW; Kalli KR; Wang C; Goode EL Tumour Biol; 2016 Oct; 37(10):13279-13286. PubMed ID: 27460076 [TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-exposed ovarian cancer cells induce cancer‑specific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression. Kim JE; Jang MJ; Jin DH; Chung YH; Choi BS; Park GB; Kim YS; Kim S; Hur DY; Hung CF; Kim D Int J Oncol; 2014 May; 44(5):1716-26. PubMed ID: 24573741 [TBL] [Abstract][Full Text] [Related]
14. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160 [TBL] [Abstract][Full Text] [Related]
15. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway. Liu YK; Jia YJ; Liu SH; Ma J Cancer Chemother Pharmacol; 2021 Mar; 87(3):405-414. PubMed ID: 33392640 [TBL] [Abstract][Full Text] [Related]
16. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells. Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503 [TBL] [Abstract][Full Text] [Related]
17. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer]. Tang XH; Lu MS; Deng S; Li M Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192 [No Abstract] [Full Text] [Related]
18. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer. Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776 [TBL] [Abstract][Full Text] [Related]
19. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Wei H; Hellström KE; Hellström I Gynecol Oncol; 2012 Jun; 125(3):727-33. PubMed ID: 22430613 [TBL] [Abstract][Full Text] [Related]
20. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells. Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]